Josie Montegaard

411 total citations
15 papers, 232 citations indexed

About

Josie Montegaard is a scholar working on Genetics, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Josie Montegaard has authored 15 papers receiving a total of 232 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Genetics, 4 papers in Hematology and 3 papers in Pathology and Forensic Medicine. Recurrent topics in Josie Montegaard's work include Chronic Lymphocytic Leukemia Research (15 papers), Advanced Breast Cancer Therapies (3 papers) and Lymphoma Diagnosis and Treatment (3 papers). Josie Montegaard is often cited by papers focused on Chronic Lymphocytic Leukemia Research (15 papers), Advanced Breast Cancer Therapies (3 papers) and Lymphoma Diagnosis and Treatment (3 papers). Josie Montegaard collaborates with scholars based in United States, Australia and Netherlands. Josie Montegaard's co-authors include Jennifer R. Brown, Matthew S. Davids, David C. Fisher, Svitlana Tyekucheva, Caron A. Jacobson, Jon Arnason, Philippe Armand, Jennifer L. Crombie, Zixu Wang and Austin I. Kim and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Lancet Oncology.

In The Last Decade

Josie Montegaard

14 papers receiving 230 citations

Peers

Josie Montegaard

GENET

PFM

IMMUN

HEMAT

PRM

Francesca Yates United Kingdom

Binsah George United States

Grégory Lazarian France

John Hanna United States

Austin I. Kim United States

Anja Engelke Germany

Sabrina Leonetti Crescenzi Italy

Francesca Maria Quaglia Italy

Gracy Zacharian United States

Iryna Kryachok Ukraine

Francesca Yates United Kingdom

Josie Montegaard

260 ×1.3

GENET

204 ×1.2

PFM

88 ×1.3

IMMUN

94 ×1.4

HEMAT

48 ×1.2

PRM

Citations per year, relative to Josie Montegaard Josie Montegaard (= 1×) peers Francesca Yates

Countries citing papers authored by Josie Montegaard

Since Specialization

Citations

This map shows the geographic impact of Josie Montegaard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Josie Montegaard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Josie Montegaard more than expected).

Fields of papers citing papers by Josie Montegaard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Josie Montegaard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Josie Montegaard. The network helps show where Josie Montegaard may publish in the future.

Co-authorship network of co-authors of Josie Montegaard

This figure shows the co-authorship network connecting the top 25 collaborators of Josie Montegaard. A scholar is included among the top collaborators of Josie Montegaard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Josie Montegaard. Josie Montegaard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Anderson, Mary Ann, Renata Walewska, Arnon P. Kater, et al.. (2024). Venetoclax Initiation in Chronic Lymphocytic Leukemia: International Insights and Innovative Approaches for Optimal Patient Care. Cancers. 16(5). 980–980. 2 indexed citations

Crombie, Jennifer L., Christine E. Ryan, Svitlana Tyekucheva, et al.. (2024). A Phase 2 Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter's Syndrome (RS). Blood. 144(Supplement 1). 4628–4628. 2 indexed citations

Davids, Matthew S., Kathleen A. Rogers, Nitin Jain, et al.. (2023). Initial results of a multicenter phase 2 study of venetoclax in combination with R‐CHOP (VR‐CHOP) for patients with Richter Syndrome. Hematological Oncology. 41(S2). 466–468. 11 indexed citations

Crombie, Jennifer L., Inhye E. Ahn, Svitlana Tyekucheva, et al.. (2023). SAVE (Safe Accelerated Venetoclax Escalation): Initial results of a prospective, phase Ib study of venetoclax with an accelerated dose ramp-up in patients with CLL.. Journal of Clinical Oncology. 41(16_suppl). 7512–7512. 2 indexed citations

Ahn, Inhye E., Yinglu Zhou, Svitlana Tyekucheva, et al.. (2023). A Phase 2 Study of Acalabrutinib, Umbralisib, and Ublituximab (AU2) in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). Blood. 142(Supplement 1). 1914–1914.

Ryan, Christine E., Jennifer L. Crombie, Svitlana Tyekucheva, et al.. (2022). Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter's Syndrome (RS). Blood. 140(Supplement 1). 9871–9872. 5 indexed citations

Davids, Matthew S., Kerry A. Rogers, Svitlana Tyekucheva, et al.. (2021). Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome. Blood. 139(5). 686–689. 44 indexed citations

Davids, Matthew S., Benjamin L. Lampson, Svitlana Tyekucheva, et al.. (2021). Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study. The Lancet Oncology. 22(10). 1391–1402. 70 indexed citations

Davids, Matthew S., Danielle M. Brander, Svitlana Tyekucheva, et al.. (2021). Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia. Blood. 138(Supplement 1). 640–640. 1 indexed citations

10.

Davids, Matthew S., David C. Fisher, Svitlana Tyekucheva, et al.. (2020). A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients. Leukemia. 35(4). 1064–1072. 26 indexed citations

11.

Davids, Matthew S., Kerry A. Rogers, Svitlana Tyekucheva, et al.. (2020). A multicenter phase II study of venetoclax plus dose-adjusted R-EPOCH (VR-EPOCH) for Richter’s syndrome.. Journal of Clinical Oncology. 38(15_suppl). 8004–8004. 9 indexed citations

12.

Crombie, Jennifer L., Svitlana Tyekucheva, Zixu Wang, et al.. (2020). Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL/SLL or Richter's Syndrome. Blood. 136(Supplement 1). 46–47. 12 indexed citations

13.

Davids, Matthew S., Benjamin L. Lampson, Svitlana Tyekucheva, et al.. (2020). Updated Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab (AVO) for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL). Blood. 136(Supplement 1). 20–21. 13 indexed citations

14.

Lampson, Benjamin L., Svitlana Tyekucheva, Jennifer L. Crombie, et al.. (2019). Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL). Blood. 134(Supplement_1). 32–32. 27 indexed citations

15.

Crombie, Jennifer L., Svitlana Tyekucheva, Alexandra Savell, et al.. (2019). A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLL. Blood. 134(Supplement_1). 1763–1763. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact